Evaxion's EVX-01 sustains clinical responses at three years in Phase 2 melanoma trial
EVAX•Evaxion said clinical responses to its personalized cancer vaccine EVX-01 remained sustained through three years in a Phase 2 trial of advanced melanoma, with no tumor progression during the third year of vaccine-only treatment.
1. Three-year trial update
Evaxion announced sustained clinical responses through three years in a Phase 2 trial of EVX-01 in advanced melanoma. No tumor progression occurred during the third year of vaccine-only treatment, and vaccine-induced immune responses remained sustained. Results are scheduled for presentation at the ESMO Congress on October 24, 2026, following two-year findings presented in 2025.
